Planforge Introduces Product Maturity Level Tracking with New Gate Management Option
13.2.2025 14:30:00 CET | Business Wire | Press release
Release 25 Also Introduces First GenAI-Powered Assistant Features and Configurable Portfolio Dashboards
Planforge today announced Planforge 25, the latest release of its industry-leading project work management software. The new version introduces the Gate Management Option (GMO), an optional module developed specifically to help track the product maturity level for development projects. With version 25, Planforge also ships their first GenAI-powered assistant features as announced late last year. The release also features more configurable portfolio dashboards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213182628/en/

Planforge 25: New Gate Management Option enables seamless product maturity tracking in development projects. (Graphic: Business Wire)
Gate Management for Development Projects
With its new Gate Management Option, Planforge builds a bridge between development processes and projects by directly integrating support for process gates into project planning. A process gate is a key decision point in a workflow where progress is evaluated to ensure criteria are met before moving to the next phase. Gates are uniquely defined on the project pipeline stage level, and can then be used in project templates and plans together with progress criteria and due dates.
Process gate criteria are based on work packages (WP) and target progress levels per WP. Therefore, the maturity level per criterion can be automatically derived based on actual WP progress. Process gate maturity levels are in turn aggregated based on criteria progress levels. Also target dates for process gates can be automatically monitored based on actual versus planned finish dates of their linked work packages.
"In the technology and automotive industries, gate management today involves a lot of manual work, as project plans are not integrated with process gates in any way," said Gerald Aquila, founder & CEO of Planforge. "With Planforge 25, we are changing the game: by directly reusing existing actual project management data for monitoring and controlling process gates we can not only save many hours of work, but also cut administrative costs significantly."
Additionally, Planforge now integrates a simple but powerful gate review process where go/no-go decisions, gate revisions, and required measures can be easily tracked in a revision-safe way. This allows for early warnings and delivers more transparency and more insightful KPIs. All gate-related information is clearly summarised in dedicated new views for gates planning and controlling, covering single and multiple projects alike.
First Assistant Features of GenAI Initiative
Planforge 25 further introduces the first assistant features of the company’s broader GenAI initiative. For instance, project managers can ask the system for suggestions for SMART (specific, measurable, achievable, realistic and time-bound) project objectives based on the current project description and additional related meta data such as linked ideas. These functions are context-sensitive, directly embedded in the main user interface (in this case, the project charter) and currently powered by OpenAI's ChatGPT.
Configurable Portfolio Dashboards
After introducing custom KPIs and configurable KPI overviews last year, Planforge 25 now also makes portfolio dashboards configurable. Just like for the KPIs view, users can now easily configure the displayed widgets via drag and drop per portfolio.
Availability
Planforge is free for up to four users. Larger teams can test the project work management software via a free 30-day trial. For more information or to be among the first to try the new Gate Management Option, please contact the Planforge sales team at info@planforge.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213182628/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom